Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics

Category Primary study
JournalJournal of Clinical Oncology
Year 2021
This article has no abstract
Epistemonikos ID: 3dbfb10b016b7a87c7e5bef6e5ae1e064a6ba7e7
First added on: Feb 13, 2025